A Phase 1 interventional study of ACT-541468 and Placebo in Obstructive Sleep Apnea, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-19.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Sleep Apnea, Obstructive with a site in Germany — 7 open to participants now, 13 under way, 5 of them phase 3. Sleep Apnea, Obstructive · Germany.
Among the 68 studies in Sleep Apnea, Obstructive with a site in Germany, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2019, is one of 2 in phase 1, and was the 46th registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →7 of the 68 studies in Sleep Apnea, Obstructive with a site in Germany are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, Australia and 8 more countries
Ages 18+
Inspire Medical Systems, Inc. · Sites in Germany, Austria, Belgium and 4 more countries
Ages 18+
Wissenschaftliches Institut Bethanien e.V · Sites in Germany, Belgium, France and 8 more countries
Ages 40+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 80 across the 55 interventional studies, 136 across the 13 observational. Of the 48 that completed or were terminated, 14 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 68 have an industry lead sponsor. The 10 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Idorsia Pharmaceuticals Ltd. has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
3 of the studies in Sleep Apnea, Obstructive with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT06970171University Medicine GreifswaldAcceptance of Mandibular Advancement Devices | 2027-05-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Sleep Apnea, Obstructive with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is conducted to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg once daily from Day 1 to Day 5 of Period A
Drug: ACT-541468
Matching placebo once daily from Day 1 to Day 5 of Period B
Drug: Placebo
Film-coated tablet for oral use
Film-coated tablet for oral use
Apnea/hypopnea index (AHI) after multiple-dose administration of ACT-541468 as measured by polysomnography (PSG)
AHI is defined by total number of apnea (pause in respiration ≥ 10 s) plus hypopnea (reduction in airflow or tidal volume from pre-event baseline by 30% for at least 10 s accompanied by a decrease of SaO2 ≥ 4%) events, divided by total sleep time (TST, in min), then multiplied by 60, during TST
Time frame: After multiple-dose administration (i.e., at Night 5) (duration: 8 hours PSG recording)
AHI during TST after single-dose administration
Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)
Mean SaO2 during TST
Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)
AHI during the awake, non-REM, and REM phases
Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)
Mean SaO2 during the awake, non-REM, and REM phases
Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)
Percentage of TST during which SaO2 is < 90%, < 85%, and < 80%
Time frame: After single-dose (i.e., Night 1) administration (duration: 8 hours PSG recording)
Change from baseline to EOP of both periods in subjective next-day performance (morning sleepiness, daytime alertness, and daytime ability to function) as assessed by VAS
Time frame: After single-dose (i.e., Night 1) and multiple-dose (i.e., Night 5) administration (duration: 2 x 8 hours PSG recording)
Objective sleep parameters LPS, WASO, TST, and SEI following single- and multiple-dose administration, as measured by PSG
Time frame: After single-dose (i.e., Night 1) and multiple-dose (i.e., Night 5) administration (duration: 2 x 8 hours PSG recording)
Safety profile including incidence of adverse events (AEs) and serious adverse events (SAEs)
Time frame: From baseline to EOS (duration: for up to 10 weeks)
Plan to share: No
Ran from Mar 2019 to primary completion in Nov 2019, 7 months.
Of 27 phase 1 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Idorsia Pharmaceuticals Ltd. →